At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Cabozantinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
In Brief
A Phase 2 clinical trial evaluating Cabozantinib and Trastuzumab for Breast Cancer and Brain Tumor - Metastatic. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
This research study is evaluating the effectiveness of the drug called cabozantinib (alone or in combination with trastuzumab) as a possible treatment for advanced breast cancer in which the cancer has spread to the brain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Brain Tumor - Metastatic
CountriesUnited States
CollaboratorsExelixis, Genentech, Inc.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2014
Primary CompletionJan 2019
Study CompletionMar 2020
TodayJul 2026
First PostedOct 9, 2014
Enrollment StartNov 1, 2014
Primary CompletionJan 4, 2019
Study CompletionMar 17, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.7 years ago
Interventions
Cabozantinibdrug
Trastuzumabdrug